134 related articles for article (PubMed ID: 37722956)
1. Effectiveness and Safety of Eliglustat Treatment in Gaucher Disease: Real-life Unicentric Experience.
Duminuco A; Fazio M; Grasso S; Gullo L; Riccobene C; Calafiore V; Markovic U; Di Raimondo F; Giuffrida G
Clin Ther; 2023 Nov; 45(11):1105-1110. PubMed ID: 37722956
[TBL] [Abstract][Full Text] [Related]
2. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients.
Smid BE; Ferraz MJ; Verhoek M; Mirzaian M; Wisse P; Overkleeft HS; Hollak CE; Aerts JM
Orphanet J Rare Dis; 2016 Mar; 11():28. PubMed ID: 27008851
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of eliglustat on skeletal manifestations in clinical trials of patients with Gaucher disease type 1.
Cox TM; Charrow J; Lukina E; Mistry PK; Foster MC; Peterschmitt MJ
Genet Med; 2023 Feb; 25(2):100329. PubMed ID: 36469032
[TBL] [Abstract][Full Text] [Related]
4. Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1.
Peterschmitt MJ; Freisens S; Underhill LH; Foster MC; Lewis G; Gaemers SJM
Orphanet J Rare Dis; 2019 Jun; 14(1):128. PubMed ID: 31174576
[TBL] [Abstract][Full Text] [Related]
5. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States.
Balwani M; Burrow TA; Charrow J; Goker-Alpan O; Kaplan P; Kishnani PS; Mistry P; Ruskin J; Weinreb N
Mol Genet Metab; 2016 Feb; 117(2):95-103. PubMed ID: 26387627
[TBL] [Abstract][Full Text] [Related]
6. Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.
Mistry PK; Lukina E; Ben Turkia H; Shankar SP; Baris H; Ghosn M; Mehta A; Packman S; Pastores G; Petakov M; Assouline S; Balwani M; Danda S; Hadjiev E; Ortega A; Gaemers SJM; Tayag R; Peterschmitt MJ
Am J Hematol; 2017 Nov; 92(11):1170-1176. PubMed ID: 28762527
[TBL] [Abstract][Full Text] [Related]
7. Real life data: follow-up assessment on Spanish Gaucher disease patients treated with eliglustat. TRAZELGA project.
Serrano-Gonzalo I; de Frutos LL; Lahoz-Gil C; Delgado-Mateos F; Fernández-Galán MÁ; Morales-Conejo M; Calle-Gordo MV; Ibarretxe-Gerediaga D; Madinaveitia-Ochoa A; Albarracin-Arraigosa A; Balanzat-Muñoz J; Correcher-Medina P; García-Frade LJ; Hernández-Rivas JM; Labbadia F; López-Dupla JM; Lozano-Almela ML; Mora-Casterá E; Noya-Pereira MS; Ruíz-Guinaldo MÁ; Del Mar Tormo-Díaz M; Vitoria-Miñana I; Arévalo-Vargas I; Andrade-Campos M; Giraldo P
Orphanet J Rare Dis; 2023 Dec; 18(1):390. PubMed ID: 38102667
[TBL] [Abstract][Full Text] [Related]
8. Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease.
Kleytman N; Ruan J; Ruan A; Zhang B; Murugesan V; Lin H; Guo L; Klinger K; Mistry PK
Mol Genet Metab Rep; 2021 Dec; 29():100798. PubMed ID: 34485083
[TBL] [Abstract][Full Text] [Related]
9. Glucosylsphingosine is a key biomarker of Gaucher disease.
Murugesan V; Chuang WL; Liu J; Lischuk A; Kacena K; Lin H; Pastores GM; Yang R; Keutzer J; Zhang K; Mistry PK
Am J Hematol; 2016 Nov; 91(11):1082-1089. PubMed ID: 27441734
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results.
Mistry PK; Lukina E; Ben Turkia H; Shankar SP; Baris Feldman H; Ghosn M; Mehta A; Packman S; Lau H; Petakov M; Assouline S; Balwani M; Danda S; Hadjiev E; Ortega A; Foster MC; Gaemers SJM; Peterschmitt MJ
Am J Hematol; 2021 Sep; 96(9):1156-1165. PubMed ID: 34161616
[TBL] [Abstract][Full Text] [Related]
11. A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: Evaluation of frequency, timing, and duration.
Peterschmitt MJ; Cox GF; Ibrahim J; MacDougall J; Underhill LH; Patel P; Gaemers SJM
Blood Cells Mol Dis; 2018 Feb; 68():185-191. PubMed ID: 28126395
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of eliglustat combined to enzyme replacement therapy for lymphadenopathy in patients with Gaucher disease type 3.
Lee NC; Chien YH; Wang CH; Wong SL; Peng SS; Tsai FJ; Hwu WL
Mol Genet Metab Rep; 2022 Jun; 31():100867. PubMed ID: 35782609
[TBL] [Abstract][Full Text] [Related]
13. Long-term eliglustat treatment of Gaucher patients over up to 10 years in Vienna.
Stulnig TM
Wien Klin Wochenschr; 2022 Jun; 134(11-12):471-477. PubMed ID: 35412052
[TBL] [Abstract][Full Text] [Related]
14. Case report of unexpected gastrointestinal involvement in type 1 Gaucher disease: comparison of eliglustat tartrate treatment and enzyme replacement therapy.
Kim YM; Shin DH; Park SB; Cheon CK; Yoo HW
BMC Med Genet; 2017 May; 18(1):55. PubMed ID: 28506293
[TBL] [Abstract][Full Text] [Related]
15. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe.
Belmatoug N; Di Rocco M; Fraga C; Giraldo P; Hughes D; Lukina E; Maison-Blanche P; Merkel M; Niederau C; Plӧckinger U; Richter J; Stulnig TM; Vom Dahl S; Cox TM
Eur J Intern Med; 2017 Jan; 37():25-32. PubMed ID: 27522145
[TBL] [Abstract][Full Text] [Related]
16. Eliglustat: A Review in Gaucher Disease Type 1.
Scott LJ
Drugs; 2015 Sep; 75(14):1669-78. PubMed ID: 26384672
[TBL] [Abstract][Full Text] [Related]
17. Budget Impact Analysis of Eliglustat for the Treatment of Gaucher Disease Type 1 in the United States.
Nalysnyk L; Sugarman R; Cele C; Uyei J; Ward A
J Manag Care Spec Pharm; 2018 Oct; 24(10):1002-1008. PubMed ID: 30247105
[TBL] [Abstract][Full Text] [Related]
18. Patient reported outcomes of patients with Gaucher disease type 1 treated with eliglustat in real-world settings: The ELIPRO study.
Camou F; Lagadec A; Coutinho A; Berger MG; Cador-Rousseau B; Gaches F; Belmatoug N
Mol Genet Metab; 2023 Nov; 140(3):107667. PubMed ID: 37597334
[TBL] [Abstract][Full Text] [Related]
19. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.
Cox TM; Drelichman G; Cravo R; Balwani M; Burrow TA; Martins AM; Lukina E; Rosenbloom B; Ross L; Angell J; Puga AC
Lancet; 2015 Jun; 385(9985):2355-62. PubMed ID: 25819691
[TBL] [Abstract][Full Text] [Related]
20. Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial.
Lukina E; Watman N; Dragosky M; Lau H; Avila Arreguin E; Rosenbaum H; Zimran A; Foster MC; Gaemers SJM; Peterschmitt MJ
Am J Hematol; 2019 Jan; 94(1):29-38. PubMed ID: 30264864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]